文献速递肝病

FGF21激动剂:代谢功能障碍相关脂肪性肝炎及更多疾病的新兴治疗选择

FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond.
PubMed 文献 · J Hepatol · 2024-05-04

综述总结FGF21类似物治疗MASH的临床前与临床数据,指出其除改善MASH消退和纤维化外还具有多效性,并探讨其他潜在治疗适应症。

要点

  • FGF21类似物对MASH消退和纤维化改善均有显著作用,并具有多效性。
  • 目前仅一种药物获批用于MASH,多种候选药物已进入III期开发阶段。
  • 综述还探讨了FGF21类似物在MASH之外的其他潜在治疗适应症。

核心结论

  • FGF21类似物因对MASH消退和纤维化改善均有显著作用且具有多效性,在未来治疗选择中占有重要位置。

研究设计与样本

  • 综述总结了FGF21类似物治疗MASH的临床前和临床数据,并探讨其他潜在治疗适应症。

主要发现

  • 肥胖、高甘油三酯血症、血脂异常、2型糖尿病和MASLD/MASH的全球流行给医疗系统带来重大经济负担。
  • at-risk MASH定义为伴有中度或显著纤维化的MASH,患者合并症/死亡风险更高,心血管疾病和/或主要不良肝脏结局风险显著。
  • 尽管医疗需求高度未满足,目前仅有一种药物获批用于MASH。
  • 多种候选药物已进入III期开发阶段,未来几年可能带来若干潜在的条件性药物批准。
  • FGF21类似物除对MASH消退和纤维化改善有显著作用外,还具有多效性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidaemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) represent a major economic burden on healthcare systems. Patients with at-risk MASH, defined as MASH with moderate or significant fibrosis, are at higher risk of comorbidity/mortality, with a significant risk of cardiovascular diseases and/or major adverse liver outcomes. Despite a high unmet medical need, there is only one drug approved for MASH. Several drug candidates have reached the phase III development stage and could lead to several potential conditional drug approvals in the coming years. Within the armamentarium of future treatment options, FGF21 analogues hold an interesting position thanks to their pleiotropic effects in addition to their significant effect on both MASH resolution and fibrosis improvement. In this review, we summarise preclinical and clinical data from FGF21 analogues for MASH and explore additional potential therapeutic indications.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Rolph T, Knott M, et al. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol. 2024. PMID: 38710230. doi:10.1016/j.jhep.2024.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。